Long Chau Partners with Viatris Vietnam to Bring Dyslipidemia Screening to Community Pharmacies

Dyslipidemia does not cause a clear enough pain for patients to remember its face. Those affected still eat well, still sleep, still go to work every day, until a cardiovascular event turns all of it into an emergency. In Vietnam, cardiovascular disease has long ranked among the leading causes of death, and dyslipidemia is one of the modifiable risk factors, provided patients know they carry it. The biggest gap is not in medication, but in detection. Many people check their blood lipids only once in their lifetime, usually when they already have an underlying condition or when their health forces them into hospital. The rest live with abnormal indices without knowing, because lipid testing has not become a habit in routine health check-ups for most Vietnamese people. The partnership between Long Chau pharmacy chain and Viatris Vietnam places the pharmacy at the frontline of screening, rather than merely a place to sell prescription drugs. This marks a fundamental departure from the traditional approach. For years, the role of pharmacies in Vietnam has been limited to distribution: customers bring a doctor's prescription, the pharmacist hands over the medication, and the transaction ends. The new model aims to turn the counter into an initial screening point, where people can receive advice, have their indices measured, and get recommendations before entering a hospital. To achieve this, the pharmacist workforce must be better trained. Not every drug seller is equipped to read a lipid test result, distinguish LDL, HDL, and triglyceride indices, and understand when a patient should be referred to a specialist. The partnership between Long Chau and Viatris Vietnam focuses on upgrading the capabilities of pharmacists, who come into contact with the public more frequently than any doctor. Cardiologists involved in the program also emphasize that managing dyslipidemia is long-term work, not a one-off test. Patients need periodic monitoring, dietary adjustment, exercise, and correct medication use. On Viatris's side, this is a pharmaceutical company whose product portfolio is tied to dyslipidemia and cardiovascular treatments. A drugmaker joining a community screening program reflects a clear industry trend: pharmaceutical firms no longer just sell medicine, they want to shape the entire patient journey, from the pre-diagnosis stage to stable treatment. If every follow-up required a hospital visit, adherence rates would be very low. Pharmacies, with wide networks and long opening hours, have a natural advantage in becoming a regular point of reminder and companionship. But that very advantage raises questions about limits. A pharmacy can measure indices and offer advice, but it cannot replace a doctor in diagnosis and prescribing. The boundary between screening and treatment must be clearly drawn, otherwise the community model can easily slide into sales. People coming for medical advice could walk away with a bag of dietary supplements. This risk lies not in technology, but in the commercial motive behind every counter. The second issue is continuity. A screening program is only valuable if those found with abnormal indices are actually brought into the treatment system. Too many community health campaigns in Vietnam end right at the screening point: measured, leaflet handed out, finished. If Long Chau and Viatris Vietnam want to leave a distinctive mark, they need to build a bridge to medical facilities where patients are confirmed, diagnosed, and prescribed treatment. The highlight of this approach is that it touches the weakest link in Vietnam's preventive healthcare: people do not lack medicine, they lack information about their own condition. Pharmacies, with tens of thousands of outlets nationwide, are the densest health infrastructure Vietnam possesses. Leveraging that network for non-communicable disease screening is a systemically sound direction, not merely a marketing gimmick. Long Chau, part of FPT Retail's pharmaceutical retail ecosystem, holds one of the largest pharmacy networks in the country, which is why Viatris chose this partner rather than building its own channel. Questions remain unanswered. What standards allow a pharmacist to conduct screening? How is public data collected, stored, and secured? Who is responsible when someone is told they are normal but is actually at high risk? An agreement between a drugmaker and a retail chain, however noble in intent, needs transparent answers so it does not become a formality. This is also what any community health program in Vietnam must confront, regardless of who the partner is. Ultimately, the value of a program like this is not measured by leaflets distributed, but by the number of people who genuinely change behavior after learning their indices. Dyslipidemia is a disease of silence, and the only way to counter silence is to place checkpoints close enough, frequent enough, and accessible enough that people cannot forget it. If pharmacies can do that, honestly and without exploiting patients' anxiety, it is a genuine step forward, not only for one company, but for a system that still lacks a preventive voice.